Medpace (NASDAQ:MEDP) CEO Sells $13,739,074.02 in Stock

Key Points

• CEO August Troendle sold 21,966 Medpace shares at an average price of $625.47, generating approximately $13.74 million. His remaining stake fell 6.1% to 338,225 shares.
• Medpace shares traded down $26.10 to $598.08, while the company reported quarterly revenue growth of 17.2% and earnings of $4.25 per share, above analyst expectations.
• Analysts maintain a generally cautious outlook, with 10 “Hold” ratings and three “Buy” ratings; the average price target is $602.27. Institutional investors own approximately 77.98% of the company.

Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 21,966 shares of the business's stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $625.47, for a total transaction of $13,739,074.02. Following the completion of the transaction, the chief executive officer owned 338,225 shares of the company's stock, valued at approximately $211,549,590.75. This trade represents a 6.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Medpace Stock Performance

Shares of Medpace stock traded down $26.10 during trading hours on Thursday, reaching $598.08. 232,765 shares of the company were exchanged, compared to its average volume of 330,847. The firm has a market cap of $16.69 billion, a PE ratio of 35.06, a PEG ratio of 2.78 and a beta of 1.15. The stock's fifty day moving average is $600.14 and its 200 day moving average is $519.59. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace's revenue was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of MEDP. Cim Investment Management Inc. lifted its position in Medpace by 7.3% in the second quarter. Cim Investment Management Inc. now owns 1,137 shares of the company's stock valued at $602,000 after acquiring an additional 77 shares during the last quarter. State Street Corp grew its holdings in shares of Medpace by 4.2% during the second quarter. State Street Corp now owns 710,895 shares of the company's stock worth $376,483,000 after purchasing an additional 28,666 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Medpace by 38.9% during the second quarter. The Manufacturers Life Insurance Company now owns 20,043 shares of the company's stock worth $10,615,000 after purchasing an additional 5,610 shares during the last quarter. Sequoia Financial Advisors LLC increased its position in shares of Medpace by 8.2% during the second quarter. Sequoia Financial Advisors LLC now owns 1,108 shares of the company's stock worth $587,000 after purchasing an additional 84 shares in the last quarter. Finally, Tidal Investments LLC increased its position in shares of Medpace by 8.0% during the second quarter. Tidal Investments LLC now owns 6,155 shares of the company's stock worth $3,260,000 after purchasing an additional 458 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on MEDP. BMO Capital Markets increased their price objective on shares of Medpace from $400.00 to $600.00 and gave the company a "market perform" rating in a research report on Friday, July 24th. Barclays set a $600.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Jefferies Financial Group restated a "hold" rating on shares of Medpace in a research note on Monday, September 14th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a $535.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Finally, Mizuho increased their price objective on Medpace from $586.00 to $665.00 and gave the company an "outperform" rating in a report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $602.27.

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.